Hyperkalemia in heart failure: current treatment and new therapeutic perspectives
Chiara Minà1, Laura Ajello1, Gabriele Di Gesaro1
1Cardiology Unit, Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, IRCCS-ISMETT, Palermo. Via Tricomi 5, 90127 Palermo, Italy.
Insights
Hyperkalemia is common in heart failure, often worsened by medications and comorbidities. New potassium binders offer improved long-term management and better heart failure treatment titration, enhancing patient prognosis.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Hyperkalemia frequently complicates heart failure due to disease pathophysiology and common therapeutic agents.
- Comorbidities like kidney failure and diabetes exacerbate potassium dysregulation in heart failure patients.
- Untreated hyperkalemia poses acute risks, while chronic elevation can necessitate reduced heart failure medication dosages, negatively impacting prognosis.
Purpose of the Study:
- To review the incidence, prognostic implications, and pathophysiological mechanisms of hyperkalemia in heart failure.
- To provide an overview of current and emerging therapeutic strategies for hyperkalemia management in heart failure.
- To highlight the potential of novel potassium binders in optimizing heart failure therapy and patient outcomes.
Main Methods:
- Literature review focusing on hyperkalemia in heart failure.
- Analysis of pathophysiological links between heart failure, its treatments, and potassium levels.
- Evaluation of therapeutic interventions, including new potassium-binding agents.
Main Results:
- Hyperkalemia is a significant issue in heart failure, influenced by disease state and medications.
- Existing treatments for hyperkalemia primarily address acute situations.
- New agents like patiromer and sodium zirconium cyclosilicate show promise for chronic management and enabling optimal heart failure drug titration.
Conclusions:
- Hyperkalemia management is critical for heart failure patients, impacting both acute risks and long-term treatment efficacy.
- Novel potassium binders represent a significant advancement, potentially improving heart failure management and patient prognosis.
- Optimizing heart failure medication through effective hyperkalemia control is a key therapeutic goal.
Abstract:
Hyperkalemia in heart failure is a condition that can occur with relative frequency because it is related to pathophysiological aspects of the disease, and favored by drugs that form the basis of chronic cardiac failure therapy. Often, associated comorbidities, such as kidney failure or diabetes mellitus can further adversely affect potassium levels. Hyperkalemia can result in acute and even severe clinical manifestations that put patients at risk. On the other hand, the finding of hyperkalemia in a chronic context can lead to a reduction in dosages or to suspension of drugs such as angiotensin-converting enzymes inhibitor, angiotensin receptor blocker, angiotensin receptor neprilysin inhibitor, and mineralcorticoid receptor antagonist, first line in the treatment of the disease, with negative effects in prognostic terms. Therapies for the correction of hyperkalemia have so far mainly concerned the treatment of acute clinical pictures. Newly developed molecules, such as patiromer or sodium zirconium cyclosilicate, now open new prospectives in the long-term management of hyperkalemia, and allow us to glimpse the possibility of a better titration of the cardinal drugs for heart failure, with consequent positive effects on patient prognosis. The aim of this review is to focus on the problem of hyperkalemia in the setting of heart failure, with particular regard to its incidence, its prognostic role, and the underlining pathophysiological mechanisms. The review also provides an overview of therapeutic strategies for correcting hyperkalemia in acute and chronic conditions, with a focus on the new potassium binders that promise to improve management of heart failure.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
01:22Heart Failure Drugs: Diuretics
01:22Heart Failure VI: Adjunct Therapies
01:30Heart Failure V: Medical Management
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Heart Failure Drugs: β-Blockers